Navigation Links
Vapotherm Announces Commercial Launch of Flowrest® Homecare Device
Date:7/26/2011

STEVENSVILLE, Md., July 26, 2011 /PRNewswire-USNewswire/ -- Vapotherm announced today the launch of Flowrest®, a High Flow Therapy device developed specifically for homecare and other low acuity environments. The initial launch will focus on the U.S. and European markets.

Vapotherm's Flowrest® is designed specifically for chronic respiratory patients in home and other extended care environments.  According to the World Health Organization, chronic respiratory diseases impact hundreds of millions of people worldwide, with asthma and COPD alone totaling almost 300 million globally.  Other chronic conditions include allergic rhinitis, pulmonary fibrosis and pulmonary hypertension.  In the U.S. alone, COPD affects more than 16 million and over 1 million patients are prescribed long-term oxygen therapy.  Flowrest® is indicated to deliver heated, humidified breathing gases via nasal cannula at flow rates from 15 to 35 liters per minute.

"In response to pre-launch demand, we are excited to begin shipping Flowrest® to our customers in the U.S. and Europe," said Nick Macmillan, Home Care Segment Manager at Vapotherm.  "The Flowrest® provides patients with a new option for respiratory assistance that overcomes the well documented issues associated with mask therapies including problems with patient compliance and comfort.  Through our patented technology, we have empowered the simple and comfortable nasal cannula to provide higher levels of respiratory support."

Robert Storey, CEO of Vapotherm, commenting on the launch stated, "We wanted to provide a solution to the constant requests we received from hospital customers for a homecare option.  Worldwide, health care systems are looking for ways to get patients out of the hospital faster and sustain them at home to minimize the risk that they will have to return to the hospital.  Flowrest® is our answer to the continuity of care in High Flow Therapy."

Vapotherm has been the leading provider of High Flow Therapy devices to hospitals for over ten years, and created the category of High Flow Nasal Cannula beginning in 2001 with its first device, the 2000i.  The Company's flagship product, the Precision Flow®, is currently used in hospitals worldwide in adult, pediatric and neonatal applications.  The Flowrest® was created to fill the need for High Flow Therapy outside of the short term acute care environment.

Vapotherm, Inc. is a privately held manufacturer of respiratory care devices for hospitals and homecare use based in Stevensville, Maryland. The Company is dedicated to the development of innovative, noninvasive respiratory therapy technologies, especially for the treatment of acute and chronic breathing disorders. For more information, visit www.vtherm.com.

Vapotherm, Inc.
198 Log Canoe Circle
Stevensville, MD 21666
Phone (410) 604-3977
Fax (410) 604-3978

Contact:  Kevin Thibodeau, Executive Vice President of Sales and Marketing
410-604-3977


'/>"/>
SOURCE Vapotherm, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vapotherm Announces Approval in Canada for New High Flow Device Designed for Heliox
2. Vapotherm Announces New Exclusive Distribution Agreement with Hippo Medical for South Korea
3. Vapotherm® Receives FDA 510(k) Clearance for Flowrest® Homecare Device
4. Vapotherm, Inc. Announces CE Mark Approval for Flowrest® Homecare Device
5. Accuray Announces Proposed Offering of $75 Million Convertible Senior Notes
6. arGEN-X Announces Non-Exclusive License With BioWa for POTELLIGENT® Technology
7. NuMe Health Announces Closing of Series A-1 Financing Round
8. Amgen Announces Webcast of 2011 Second Quarter Financial Results
9. Lanx, Inc. Announces Aspen™ Spinous Process Fixation System Clinical Data at IMAST
10. Prasco® Announces Authorized Generic Agreement with Shionogi Inc.
11. Cornerstone Pharmaceuticals Announces The Journal of Molecular Medicines Publication of Research Showing Selective Inhibition of Cancer Cell Energy Metabolism With Its Novel Lipoate Derivative Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
(Date:9/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will host its ... on Friday, November 3, 2017, beginning at 7:00 a.m. ... 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... and guidance for 2018, Hill-Rom executives will also highlight ... and long-range financial outlook through 2020. ...
Breaking Medicine Technology:
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
Breaking Medicine News(10 mins):